New telehealth program aims to ease depression and fatigue in latino cancer patients
NCT ID NCT07225088
First seen Jun 26, 2026 · Last updated Sep 11, 2026 · Updated 4 times
Summary
This study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, tired, or have trouble sleeping. The program is delivered through telehealth (video or phone calls). Researchers want to see if it is practical and acceptable to patients. About 125 patients and their mental health providers will take part.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- DESCANSO/REST behavioral intervention (telehealth mental health support)
- What this could lead to
- If successful, this could provide a practical, culturally tailored mental health program for Spanish-speaking Latino cancer patients to ease depression, insomnia, and fatigue.
- What could go wrong
- This is a small feasibility study (125 participants) focused on whether the program is acceptable and doable, not on proving it works. It may not show clear benefits or be generalizable to all Latino patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 125 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jul 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Provider Eligibility Criteria: Participant eligibility will be determined by a self-report screener. Inclusion Criteria Self-Report Criteria * Mental health provider * Treats Latino cancer patients and/or survivors * Has at least 3 years of clinical experience providing psychosocial services to cancer patients and/or survivors * Able to read Spanish determined by the question: "Can you read in Spanish? Yes/No" Patient Eligibility Criteria: A patient cannot be considered eligible for this study unless ALL of the following conditions are met. Participant eligibility will be determined by an initial EMR review followed by a self-report screener. Inclusion Criteria EMR Criteria * Documentation of Disease o Pathologically confirmed solid tumor cancer (either most recent or new diagnosis) * Definition of Disease \[or Measurable Disease\] o Diagnosed with stages I, II, or III * Prior Treatment * Currently undergoing systemic therapy (chemotherapy, radiation therapy, and/or immunotherapy) or within the first year following completion of systemic therapy Self-Report Criteria * Age ≥ 21 years * Lives in mainland U.S. or Puerto Rico * Identifies as Latino/a or Hispanic * Reports Spanish as their preferred language * Speaks Spanish "Very well" or "Well" as determined by the question: "How well do you speak Spanish?" * Presence of fatigue and disturbed sleep determined by a score of ≥ 3 on the MD Anderson Symptom Inventory Exclusion Criteria EMR Criteria o In the judgment of the treating physician, protocol investigators, and/or study staff, presence of cognitive impairment (e.g., delirium or dementia) sufficient to preclude meaningful informed consent and/or study participation Self-Report Criteria * History of comorbidities within the last 12 months associated with fatigue and poor sleep, including hypothyroidism or abnormal thyroid function, sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, alcohol or drug abuse * Pregnant or lactating, women only * Presence of suicidal risk determined by any affirmative response on the Columbia-Suicide Severity Rating Scale
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Solid tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
7 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited Protocol Activites)
RECRUITINGRockville Centre, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity)
RECRUITINGCommack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITINGHarrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
- Can a new drug shield kidneys from chemotherapy damage?
- Mining Responders' tumors for clues to a universal cancer therapy
- Proton boost radiotherapy aims to hit large tumors harder while sparing healthy tissue
- New antibody aims to preserve immune checkpoint while fighting cancer
- Engineered immune cells target two markers on Hard-to-Treat tumors